Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Oct 19, 9:10 AMPacBio enters multi-year strategic collaboration with Verily to integrate HiFi long-read sequencing into Verily data and AI platform
Index
RUT
Market Cap
615.45M
Enterprise Value
1.08B
Income
-131.39M
Sales
159.27M
Book/sh
-0.11
Cash/sh
0.76
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
485
IPO
Oct 27, 2010
P/E
-
Forward P/E
-
PEG
-
P/S
3.86
P/B
-
P/C
2.60
P/FCF
-
EV/EBITDA
-
EV/Sales
6.81
Quick Ratio
4.03
Current Ratio
4.92
Debt/Eq
-
LT Debt/Eq
-
Option/Short
Yes / Yes
EPS (ttm)
-0.43
EPS next Y
-0.45
EPS next Q
-0.13
EPS this Y
74.10%
EPS next Y
5.00%
EPS next 5Y
41.41%
EPS past 3/5Y
-9.18% -
Sales past 3/5Y
7.64% 15.19%
EPS Y/Y TTM
75.85%
Sales Y/Y TTM
2.02%
EPS Q/Q
-3.08%
Sales Q/Q
-1.91%
Insider Own
8.56%
Insider Trans
-2.52%
Inst Own
53.88%
Inst Trans
1.16%
ROA
-16.66%
ROE
-929.32%
ROIC
-19.56%
Gross Margin
34.29%
Oper. Margin
-101.67%
Profit Margin
-82.49%
SMA20
-7.24%
SMA50
20.12%
SMA200
24.00%
Trades
Shs Outstand
310.81M
Shs Float
284.22M
52W High
3.43 -42.36%
52W Low
1.07 85.05%
Volatility
10.74% 13.83%
ATR (14)
0.24
RSI (14)
51.48
Beta
2.24
Rel Volume
0.10
Avg Volume
10.92M
Volume
52,122
Perf Week
-0.50%
Perf Month
34.69%
Perf Quarter
41.43%
Perf Half Y
15.79%
Perf YTD
5.88%
Perf Year
4.21%
Perf 3Y
-73.21%
Perf 5Y
-92.26%
Perf 10Y
-78.02%
Prev Close
1.96
Price
1.98
Change %
1.02%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gibson James R IISee RemarksOct 06 '26Option Exercise1.18500,000590,0001,745,663Oct 08 04:07 PM
Gibson James R IISee RemarksOct 06 '26Sale3.11661,8152,056,9211,083,848Oct 08 04:07 PM
Jim GibsonOfficerOct 06 '26Proposed Sale2.87661,8151,899,409Oct 06 04:23 PM
Van Oene MarkSee RemarksAug 17 '26Sale1.1326,91130,4092,705,853Aug 18 08:17 PM
MARK VAN OENEOfficerAug 17 '26Proposed Sale1.1326,91130,512Aug 17 04:08 PM
Gibson James R IISee RemarksApr 01 '26Sale1.3788,185120,8131,245,663Apr 03 04:05 PM
JAMES GIBSONOfficerApr 01 '26Proposed Sale1.3788,185120,778Apr 01 05:17 PM
HENRY CHRISTIAN OSee RemarksMar 03 '26Sale1.5112,49718,9203,581,813Mar 04 05:55 PM
Van Oene MarkSee RemarksMar 03 '26Sale1.516,5049,8472,243,634Mar 04 05:54 PM
Farmer MicheleSee RemarksMar 03 '26Sale1.512,9794,510305,948Mar 04 05:54 PM
MARK D. VAN OENEOfficerMar 03 '26Proposed Sale1.516,5049,849Mar 03 04:24 PM
CHRISTIAN HENRYOfficerMar 03 '26Proposed Sale1.5112,49718,924Mar 03 04:20 PM
Van Oene MarkSee RemarksFeb 17 '26Sale1.58129,790204,5491,797,745Feb 19 08:33 PM
Van Oene MarkSee RemarksFeb 18 '26Sale1.6355,10789,7691,742,638Feb 19 08:33 PM
HENRY CHRISTIAN OSee RemarksFeb 17 '26Sale1.58331,793522,9062,814,374Feb 19 08:31 PM
HENRY CHRISTIAN OSee RemarksFeb 18 '26Sale1.63140,874229,4842,673,500Feb 19 08:31 PM
Farmer MicheleSee RemarksFeb 17 '26Sale1.5835,21555,499234,044Feb 19 08:28 PM
Farmer MicheleSee RemarksFeb 18 '26Sale1.6314,95224,357219,092Feb 19 08:28 PM
MARK VAN OENEOfficerFeb 17 '26Proposed Sale1.58303,739478,693Feb 17 06:27 PM
CHRISTIAN HENRYOfficerFeb 17 '26Proposed Sale1.58606,312955,548Feb 17 06:25 PM
Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. It operates through the following geographical segments: America, Europe, Middle East, and Africa, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.
CEOMr. Mark Van Oene Ph.D.
CFO & Principal Accounting OfficerMr. James R. Gibson II
Senior Business Advisor & DirectorMr. Christian O. Henry M.B.A.
Co-FounderDr. Stephen Turner Ph.D.
Ph.D.Dr. Brett Atkins J.D.
Last Close
240.27
Oct 21 • 9:26 AM ET Dollar change-1.81 Percentage change(-0.75%)
MRNA Moderna Inc daily Stock Chart
Index
NDX, S&P 500
Market Cap
95.92B
Enterprise Value
92.07B
Income
-3.15B
Sales
2.23B
Book/sh
16.94
Cash/sh
12.87
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
4700
IPO
Dec 07, 2018
P/E
-
Forward P/E
-
PEG
-
P/S
43.05
P/B
14.18
P/C
18.67
P/FCF
-
EV/EBITDA
-
EV/Sales
41.33
Quick Ratio
2.18
Current Ratio
2.29
Debt/Eq
0.19
LT Debt/Eq
0.18
Option/Short
Yes / Yes
EPS (ttm)
-7.98
EPS next Y
-4.77
EPS next Q
-1.07
EPS this Y
-14.68%
EPS next Y
42.66%
EPS next 5Y
27.54%
EPS past 3/5Y
- -29.93%
Sales past 3/5Y
-53.32% 19.33%
EPS Y/Y TTM
-6.22%
Sales Y/Y TTM
-27.62%
EPS Q/Q
7.60%
Sales Q/Q
2.11%
Insider Own
8.51%
Insider Trans
-2.51%
Inst Own
80.34%
Inst Trans
2.20%
ROA
-27.43%
ROE
-39.00%
ROIC
-39.41%
Gross Margin
12.57%
Oper. Margin
-149.01%
Profit Margin
-141.43%
SMA20
14.55%
SMA50
45.15%
SMA200
198.55%
Trades
Shs Outstand
399.00M
Shs Float
365.28M
52W High
243.98 -1.52%
52W Low
22.28 978.41%
Volatility
11.06% 8.78%
ATR (14)
16.81
RSI (14)
67.26
Beta
1.18
Rel Volume
0.29
Avg Volume
19.28M
Volume
283,271
Perf Week
6.17%
Perf Month
31.61%
Perf Quarter
321.38%
Perf Half Y
332.14%
Perf YTD
714.75%
Perf Year
774.03%
Perf 3Y
198.84%
Perf 5Y
-29.24%
Perf 10Y
-
Prev Close
242.08
Price
240.27
Change %
-0.75%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hoge StephenPresidentOct 14 '26Option Exercise12.2176,453933,4911,638,482Oct 16 04:09 PM
Hoge StephenPresidentOct 15 '26Option Exercise12.2176,452933,4791,675,710Oct 16 04:09 PM
Hoge StephenPresidentOct 15 '26Sale220.7239,1458,640,0841,636,565Oct 16 04:09 PM
Hoge StephenPresidentOct 14 '26Sale213.4839,2248,373,4531,599,258Oct 16 04:09 PM
Hoge StephenOfficerOct 15 '26Proposed Sale220.7239,1458,640,033Oct 15 10:32 AM
Hoge StephenOfficerOct 14 '26Proposed Sale213.4839,2248,373,519Oct 14 09:58 AM
Hoge StephenPresidentSep 14 '26Option Exercise12.2176,453933,4911,566,152Sep 16 04:48 PM
Hoge StephenPresidentSep 15 '26Option Exercise12.2176,452933,4791,602,310Sep 16 04:48 PM
Hoge StephenPresidentSep 15 '26Sale146.0740,2815,883,8461,562,029Sep 16 04:48 PM
Hoge StephenPresidentSep 14 '26Sale144.1340,2945,807,5741,525,858Sep 16 04:48 PM
Hoge StephenOfficerSep 15 '26Proposed Sale146.0740,2815,883,709Sep 15 10:46 AM
Mock James MChief Financial OfficerSep 10 '26Option Exercise30.9619,836614,12394,211Sep 14 04:25 PM
Mock James MChief Financial OfficerSep 10 '26Sale134.4934,8364,685,09459,375Sep 14 04:25 PM
Hoge StephenOfficerSep 14 '26Proposed Sale144.1340,2945,807,746Sep 14 02:39 PM
Mock James MOfficerSep 10 '26Proposed Sale134.4934,8364,685,094Sep 10 10:14 AM
Klinger Shannon ThymeChief Legal OfficerSep 01 '26Option Exercise30.963,471107,46277,600Sep 03 04:56 PM
Klinger Shannon ThymeChief Legal OfficerSep 01 '26Sale139.953,471485,76674,129Sep 03 04:56 PM
Klinger Shannon ThymeOfficerSep 01 '26Proposed Sale139.953,471485,766Sep 01 11:22 AM
Bancel StephaneChief Executive OfficerAug 05 '26Option Exercise19.15499,2469,560,5616,687,037Aug 07 04:11 PM
Bancel StephaneChief Executive OfficerAug 06 '26Option Exercise19.15252,4694,834,7816,440,260Aug 07 04:11 PM
Bancel StephaneChief Executive OfficerAug 05 '26Sale57.52499,24628,715,0116,187,791Aug 07 04:11 PM
Bancel StephaneOfficerAug 05 '26Proposed Sale58.00499,24628,956,268Aug 05 01:02 PM
Hoge StephenPresidentJul 15 '26Option Exercise19.1553,3361,021,3841,537,184Jul 16 04:45 PM
Hoge StephenPresidentJul 15 '26Sale67.6053,3363,605,5141,483,848Jul 16 04:45 PM
Hoge StephenOfficerJul 15 '26Proposed Sale67.6053,3363,605,514Jul 15 10:22 AM
SAGAN PAULFormer DirectorJun 18 '26Proposed Sale64.5725,7701,663,875Jun 18 03:26 PM
Hoge StephenPresidentJun 15 '26Option Exercise19.1553,3361,021,3841,537,184Jun 17 04:10 PM
Hoge StephenPresidentJun 15 '26Sale51.3753,3362,739,8701,483,848Jun 17 04:10 PM
Hoge StephenOfficerJun 15 '26Proposed Sale51.3753,3362,739,870Jun 15 11:43 AM
Klinger Shannon ThymeChief Legal OfficerJun 04 '26Option Exercise30.963,471107,46270,939Jun 08 04:34 PM
Klinger Shannon ThymeChief Legal OfficerJun 04 '26Sale50.003,471173,55067,468Jun 08 04:34 PM
Klinger Shannon ThymeOfficerJun 04 '26Proposed Sale50.003,471173,550Jun 04 01:26 PM
AFEYAN NOUBARDirectorMay 21 '26Option Exercise19.159,263177,38613,187May 22 07:00 PM
AFEYAN NOUBARDirectorMay 21 '26Sale46.849,263433,8793,924May 22 07:00 PM
Flagship Pioneering, LLCAffiliateMay 21 '26Proposed Sale46.849,263433,880May 21 03:06 PM
Hoge StephenPresidentMay 15 '26Option Exercise19.1553,3361,021,3841,531,333May 18 04:57 PM
Hoge StephenPresidentMay 15 '26Sale48.4053,3362,581,4621,477,997May 18 04:57 PM
Hoge StephenOfficerMay 15 '26Proposed Sale48.4053,3362,581,462May 15 09:47 AM
SAGAN PAULFormer DirectorMay 08 '26Proposed Sale54.4836,7592,002,787May 08 11:24 AM
Hussain AbbasDirectorMay 01 '26Sale46.635,682264,95212,066May 04 05:25 PM
Hussain AbbasDirectorMay 01 '26Proposed Sale46.635,682264,952May 01 11:44 AM
Klinger Shannon ThymeChief Legal OfficerMar 02 '26Option Exercise30.9613,885429,88073,574Mar 03 04:10 PM
Klinger Shannon ThymeChief Legal OfficerMar 02 '26Sale52.2913,885726,04759,689Mar 03 04:10 PM
Klinger Shannon ThymeOfficerMar 02 '26Proposed Sale52.2913,885726,047Mar 02 09:56 AM
Hoge StephenPresidentFeb 23 '26Option Exercise19.15160,0093,064,1721,617,436Feb 25 04:49 PM
Hoge StephenPresidentFeb 23 '26Sale48.84160,0097,814,8401,457,427Feb 25 04:49 PM
Hoge StephenOfficerFeb 23 '26Proposed Sale48.84160,0097,814,840Feb 23 10:26 AM
AFEYAN NOUBARDirectorDec 11 '25Option Exercise10.9023,853259,99827,777Dec 15 09:00 AM
AFEYAN NOUBARDirectorDec 11 '25Sale29.4823,853703,3063,924Dec 15 09:00 AM
Bancel StephaneChief Executive OfficerDec 11 '25Option Exercise10.90688,0737,499,9966,181,970Dec 15 08:59 AM
Flagship Pioneering Inc.AffiliateDec 11 '25Proposed Sale29.4923,853703,306Dec 11 04:30 PM
Hussain AbbasDirectorDec 09 '25Sale27.6050413,9101,515Dec 11 04:16 PM
Hussain AbbasDirectorDec 09 '25Proposed Sale27.6050413,910Dec 09 10:26 AM
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
CEO & DirectorMr. Stephane Bancel M.B.A.
PresidentDr. Stephen Hoge M.D.
Chief Financial OfficerMr. James M. Mock
Chief Legal Officer & Corporate SecretaryMs. Shannon Thyme Klinger J.D.
Chief Operating OfficerMr. Juan Andres